Salix's AIDS/HIV-related diarrhea drug Fulyzaq gets FDA nod

01/1/2013 | Reuters · American City Business Journals

Salix Pharmaceuticals' Fulyzaq, or crofelemer, has been approved by the FDA to treat diarrhea in HIV/AIDS patients undergoing antiretroviral therapy. This makes Fulyzaq, developed by Napo Pharmaceuticals, the first approved treatment for HIV/AIDS patients whose diarrhea is not caused by bacteria, virus or parasite.

View Full Article in:

Reuters · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX